{"filings":[{"id":1415118,"accession_number":"0001159036-26-000088","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2026-07-02T20:10:08+00:00","items":["5.02"],"status":"ready","headline":"Halozyme announces departure of COO Cortney Caudill","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cortney Caudill departed as SVP, Chief Operating Officer on June 30, 2026.","No replacement has been named; company thanked Caudill for her contributions.","Departure is part of an update to senior management structure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":12925,"accession_number":"0001159036-26-000067","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2026-05-11T20:06:06+00:00","items":["2.02","9.01"],"status":"ready","headline":"Halozyme Q1 revenue up 42% to $377M; new $1B buyback program","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $376.7M (+42% YoY); royalty revenue $240.7M (+43% YoY).","GAAP diluted EPS $1.22 (vs $0.93); Non-GAAP diluted EPS $1.60 (vs $1.11).","New $1B share repurchase program through 2028; at least $400M expected in 2026.","Reiterated 2026 guidance: revenue $1.71B-$1.81B, Non-GAAP EPS $7.75-$8.25.","Collaborations: GSK (multiple oncology ENHANZE targets), argenx VYVGART Hytrulo FDA-approved for all gMG serotypes."],"consensus_eps_estimate":1.5606,"consensus_eps_actual":1.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":376708000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91592,"accession_number":"0001159036-26-000057","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Halozyme stockholders elect directors, approve say-on-pay, ratify auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors Connaughton and Posard elected with 89.1M and 82.7M votes for, respectively.","Advisory vote on executive compensation approved: 84.7M for, 9.3M against.","Ratification of Ernst & Young as FY2026 auditor passed with 103.2M votes for.","Over 104.1M of 118.5M outstanding shares were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91591,"accession_number":"0001159036-26-000053","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Halozyme names Darren Snellgrove as CFO, effective June 8, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Darren Snellgrove appointed CFO effective June 8, 2026; previously VP IR at Johnson & Johnson and CFO of its Pharmaceuticals sector.","Compensation: $670,000 annual salary, 50% bonus target, $350,000 sign-on cash bonus, and $7.2M new-hire equity awards ($3.2M RSUs + $4M options).","2027 long-term incentive minimum $4M; make-whole RSUs vest over 3 years, stock options vest 25% after 1 year then monthly.","David Ramsay, interim CFO, will assume advisory role effective June 8, 2026 to assist transition.","Snellgrove holds MBA from Villanova, BA from University of Southampton; no family relationships or material interests in transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91590,"accession_number":"0001159036-26-000051","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Halozyme amends bylaws to allow director removal with or without cause by majority vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board amended Section 2.5 to permit removal of directors at any time, with or without cause, by majority of shares entitled to vote.","Section 1.12 amended to clarify stockholder actions cannot be taken without a meeting, consistent with the Certificate of Incorporation.","Amendments adopted by Board on April 22, 2026; full text filed as Exhibit 3.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101795,"accession_number":"0001159036-26-000035","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Halozyme appoints David Ramsay as Interim CFO effective March 23, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Monthly salary of $50,000; initial grant of 10,000 RSUs vesting June 30, 2026, plus 2,500 more if still interim after July 1.","Ramsay previously served as Halozyme CFO from 2003-2009 and 2013-2015, and guided company from private to public.","Company is actively searching for a permanent CFO via a leading executive search firm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101794,"accession_number":"0001159036-26-000023","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Halozyme full-year 2025 revenue $1.397B (up 38%), royalty record $868M; 2026 guidance reiterated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 total revenue $1.397B (+38% YoY); royalty revenue $868M (+52%) led by VYVGART Hytrulo, DARZALEX SC, Phesgo.","GAAP net income $316.9M ($2.56 diluted EPS) includes $284.9M IPR&D charge for Surf Bio acquisition; adjusted EBITDA $657.6M.","Q4 2025 revenue $451.8M (+52% YoY); net loss $141.6M due to Surf Bio charge; adjusted EBITDA $21.9M.","2026 guidance: total revenue $1.71–1.81B (growth 22–30%), royalty $1.13–1.17B, adjusted EBITDA $1.125–1.205B, non-GAAP EPS $7.75–8.25.","Expanded delivery portfolio via Elektrofi and Surf Bio acquisitions; completed $1.5B convertible note offering."],"consensus_eps_estimate":2.242,"consensus_eps_actual":2.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":1396611000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101793,"accession_number":"0001159036-26-000011","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Halozyme raises 2026 guidance; acquires Surf Bio for $300M upfront","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary 2025 revenue estimated at $1,385-1,400M (+36-38% YoY); royalties $865-870M (+51-52% YoY).","2026 revenue guidance raised to $1,710-1,810M (+23-30% YoY) from prior $1,430-1,530M; royalty revenue now >$1B.","2026 non-GAAP diluted EPS guidance raised to $7.75-8.25 (prior $6.50-7.00); Adjusted EBITDA $1,125-1,205M.","Acquired Surf Bio for $300M upfront plus up to $100M milestones; adds hyperconcentration technology for biologics.","Surf Bio technology enables 500 mg/mL antibody concentrations for single auto-injector subcutaneous delivery."],"consensus_eps_estimate":2.242,"consensus_eps_actual":2.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":1396611000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118125,"accession_number":"0001159036-25-000070","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Halozyme awards CEO $10M performance-based RSUs tied to stock price targets $115-$170","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Compensation Committee approved one-time PSU grant for CEO Dr. Helen Torley with $10M target fair value.","Shares vest based on achieving 20-trading-day average stock price of $115 (50%), $130 (100%), $145 (150%), or $170 (200%) over 4-year performance period.","Time-based vesting requires continued employment through fourth anniversary; voluntary resignation/retirement forfeits all performance-vested shares.","Grant intended to retain CEO and incentivize growth and profitability during next stage."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118124,"accession_number":"0001159036-25-000068","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Halozyme elects James Lang to Board of Directors, term through 2027 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Lang elected to Halozyme's Board on December 4, 2025.","Mr. Lang's term expires at the 2027 annual meeting of stockholders.","No Board committee assignments initially made.","Compensation follows standard non-employee director program as described in the 2025 proxy.","No related party transactions or arrangements exist with Mr. Lang."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118123,"accession_number":"0001159036-25-000061","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2025-11-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Halozyme CFO Nicole LaBrosse to depart by March 30, 2026 under transition agreement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Nicole LaBrosse will remain until new CFO is hired or March 30, 2026, whichever comes first.","Transition agreement provides 120% target bonus for 2025, severance equal to base salary plus pro-rated 2026 bonus.","Equity awards vesting through February 28, 2026 will accelerate; option exercise period extended to one year post-separation.","If a Change in Control occurs within one year after separation, unvested options will fully vest.","COBRA coverage premiums paid for one year; agreement filed with 2025 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118122,"accession_number":"0001193125-25-277988","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Halozyme issues $1.5B in convertible notes; repurchases $1.02B of existing notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $750M 0% convertible notes due 2031 and $750M 0.875% notes due 2032; net proceeds ~$1.47B.","Used ~$1.02B to repurchase 0.25% notes due 2027 and 1.00% notes due 2028 via private transactions.","Entered capped call transactions ($182.7M) to limit dilution; cap price $136.78 vs conversion price $87.20.","Remaining proceeds for general corporate purposes, potential acquisitions, and future note repurchases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118121,"accession_number":"0001159036-25-000049","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Halozyme prices $1.3B convertible notes offering; to repurchase ~$1.02B of existing 2027/2028 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Priced $650M of 0% convertible notes due 2031 and $650M of 0.875% notes due 2032; initial purchasers have 13-day option for additional $200M.","Initial conversion price of ~$87.20/share, a 27.5% premium over the $68.39 closing price on Nov. 6, 2025.","Net proceeds of ~$1.274B ($1.47B if option exercised); ~$1.019B to repurchase outstanding 0.25% 2027 and 1.00% 2028 notes.","Entered into capped call transactions with cap price of $136.78/share to reduce potential dilution upon conversion.","Expected to close offering on November 12, 2025; remainder of proceeds for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118120,"accession_number":"0001159036-25-000047","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Halozyme to offer $1.3B in convertible notes; extends credit facility to $750M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amended credit facility: commitments increased to $750M, maturity extended to Nov 5, 2030; no outstanding borrowings.","Proposes $650M 2031 notes and $650M 2032 notes; option for additional $100M each.","Net proceeds partly fund capped call transactions to reduce potential dilution upon conversion.","Plans to repurchase existing 0.25% 2027 and 1.00% 2028 convertible notes via private deals.","Remaining proceeds for general corporate purposes, including working capital and acquisitions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118119,"accession_number":"0001159036-25-000044","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Halozyme Q3 revenue up 22%, raises 2025 guidance, CFO transition announced","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 revenue $354M (+22% YoY); royalty revenue $236M (+52% YoY); GAAP diluted EPS $1.43 (+36% YoY); non-GAAP diluted EPS $1.72 (+35% YoY).","Raises full-year 2025 guidance: total revenue $1,300-$1,375M, royalty $850-$880M, Adj. EBITDA $885-$935M, non-GAAP EPS $6.10-$6.50.","Agreed to acquire Elektrofi for $750M up-front plus up to $150M in milestones; expected close Q4 2025.","CFO Nicole LaBrosse to depart by March 30, 2026 or when successor hired; external search underway; departure not due to disagreement.","Two new indication approvals: DARZALEX SC for smoldering multiple myeloma in Europe; VYVDURA prefilled syringe in Japan."],"consensus_eps_estimate":1.6609,"consensus_eps_actual":3.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":944844000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118118,"accession_number":"0001159036-25-000039","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Halozyme issues position statement on CMS final IPAY 2028 Medicare negotiation guidance","summary_kind":"llm","event_type":"regulatory","confidence":"low","bullets":["Statement includes long-term projections of U.S. Medicare Part B spend as % of total ENHANZE partner product SC sales.","No specific financial projections or quantitative details were disclosed in the 8-K or attached exhibit.","The exhibit text provided is only a title; substantive content must be accessed on the company's website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118117,"accession_number":"0001159036-25-000036","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Halozyme appoints Cortney Caudill as COO; base salary $600K, equity award $500K","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cortney Caudill appointed SVP, COO effective Oct 1, 2025; previously SVP, Chief Operations Officer since Oct 2023.","Annual base salary set at $600,000; eligible for executive incentive plans with 2025 bonus target of 50% of salary.","Receives $500K equity award (50% stock options, 50% RSUs) vesting over four years.","No family relationships or material interests in any transactions with the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118116,"accession_number":"0001193125-25-230348","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Halozyme to acquire Elektrofi for $750M upfront plus up to $150M in milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Halozyme will pay $750M cash upfront for Elektrofi, subject to customary adjustments for debt, cash, expenses, and net working capital.","Up to three $50M milestone payments conditional on separate product regulatory approvals.","Reverse termination fee of $36M payable by Halozyme if agreement terminated under certain circumstances.","Transaction expected to close within 12 months, subject to HSR and other customary closing conditions.","Certain employee options assumed and converted into Halozyme options, reducing cash consideration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118115,"accession_number":"0001193125-25-225853","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Halozyme to acquire Elektrofi for $750M upfront, expanding drug delivery offerings into 2040s","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront payment $750M; up to three $50M milestones contingent on product regulatory approvals.","Hypercon technology enables 400-500 mg/ml concentrations, up to 4-5x standard aqueous formulations.","Two partner products expected to begin clinical development by year-end 2026 or earlier.","Royalty revenue expected to begin 2030; deal less than 5% dilutive to Non-GAAP EPS over medium term.","Halozyme reaffirms 2025 guidance: rev $1.275-1.355B, Adj EBITDA $865-915M, Non-GAAP EPS $6.00-6.40."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134570,"accession_number":"0001159036-25-000033","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Halozyme Q2 revenue $326M (+41% YoY); raises FY25 guidance, files patent suit vs Merck","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $325.7M (+41% YoY); royalty revenue $205.6M (+65% YoY).","GAAP diluted EPS $1.33 (+85% YoY); Non-GAAP diluted EPS $1.54 (+69% YoY).","Raises 2025 total revenue guidance to $1.275-1.355B (26-33% YoY) and Non-GAAP EPS to $6.00-6.40.","Completed $303M share repurchases in Q2; initiated third $250M tranche under $750M program.","Filed patent infringement lawsuit against Merck alleging unauthorized use of MDASE technology for SC Keytruda."],"consensus_eps_estimate":1.2913,"consensus_eps_actual":2.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":590580000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151427,"accession_number":"0001159036-25-000025","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Halozyme Q1 revenue up 35% to $265M; raises FY25 guidance, announces $250M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $264.9M (+35% YoY); GAAP EPS $0.93 (+55%); non-GAAP EPS $1.11 (+41%).","Raised 2025 guidance: revenue $1.2-1.28B (prev $1.15-1.225B), adj. EBITDA $790-840M, non-GAAP EPS $5.30-5.70.","Announced new $250M share repurchase; completed first $250M ASR in March 2025.","Filed patent infringement lawsuit against Merck over MDASE for subcutaneous Keytruda."],"consensus_eps_estimate":null,"consensus_eps_actual":0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":264861000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151426,"accession_number":"0001159036-25-000022","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Halozyme stockholders elect two Class III directors and approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jeffrey W. Henderson elected with 98,993,463 votes for, 3,298,117 against; Helen I. Torley elected with 101,477,199 for, 816,675 against.","Say-on-pay proposal approved: 98,252,464 for, 3,966,034 against, 168,127 abstain.","Ratification of Ernst & Young as 2025 auditor approved: 112,028,211 for, 659,976 against, 78,816 abstain.","Meeting held May 1, 2025; 112,767,003 shares represented out of 123,533,310 outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170308,"accession_number":"0001159036-25-000020","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Halozyme CTO Michael J. LaBarre retires effective March 17, 2025; no successor named","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael J. LaBarre, SVP and Chief Technical Officer, retired effective March 17, 2025.","LaBarre notified the company of his decision on the same date.","He was recognized for contributions to the ENHANZE drug delivery technology.","No replacement has been announced for the CTO role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170307,"accession_number":"0001159036-25-000008","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Halozyme reports record 2024 revenue of $1.015B, Q4 net income up 60% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $298M (+30% YoY); royalty revenue $170M (+40% YoY).","Q4 GAAP EPS $1.06 (+63% YoY); non-GAAP EPS $1.26 (+54% YoY).","Full-year 2024 total revenue $1,015M (+22% YoY); net income $444M (+58% YoY).","Full-year adjusted EBITDA $632M (+48% YoY), exceeding guidance.","Reiterates 2025 guidance: total revenue $1,150-1,225M, non-GAAP EPS $4.95-5.35."],"consensus_eps_estimate":null,"consensus_eps_actual":3.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":1015324000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170306,"accession_number":"0001159036-25-000005","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Halozyme director Connie Matsui to leave board after nearly 18 years","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Connie Matsui notified Halozyme on Feb 11, 2025 she will not stand for reelection at the 2025 annual meeting.","Matsui served on the board for nearly 18 years; departure is not due to any disagreement with the company.","No replacement has been announced; the board thanked Matsui for her service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170305,"accession_number":"0001159036-25-000003","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Halozyme raises 2025 guidance: rev $1.15-1.225B, adj EBITDA $755-805M, $250M ASR","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Raises 2025 total revenue guidance to $1,150-$1,225M, representing 16-23% YoY growth from 2024 midpoint.","Raises 2025 adjusted EBITDA guidance to $755-$805M (24-32% YoY) and non-GAAP diluted EPS to $4.95-$5.35 (21-30% YoY).","Announces new $250M accelerated share repurchase (ASR) under existing $750M share repurchase program.","Reiterates 2024 preliminary unaudited guidance: revenue $970-$1,020M, adjusted EBITDA $595-$625M, non-GAAP EPS $4.00-$4.20."],"consensus_eps_estimate":null,"consensus_eps_actual":3.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":1015324000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187310,"accession_number":"0001159036-24-000049","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Halozyme Q3 revenue up 34% to $290M; raises full-year guidance on strong royalty growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $290.1M (+34% YoY); royalty revenue $155.1M (+36% YoY).","GAAP diluted EPS $1.05 (+72% YoY); Non-GAAP diluted EPS $1.27 (+69% YoY).","2024 guidance raised: revenue $970M-$1.02B, Adj. EBITDA $595M-$625M, Non-GAAP EPS $4.00-$4.20.","argenx expanded ENHANZE deal (4 new targets) for $30M upfront; ViiV added another target.","Cash and securities $666.3M, up from $336M at Dec 2023, driven by operations."],"consensus_eps_estimate":null,"consensus_eps_actual":2.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":717316000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203815,"accession_number":"0001159036-24-000043","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Halozyme beats Q2 with $231M revenue, $0.91 non-GAAP EPS; reiterates raised 2024 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $231M (+5% YoY), net income $93M (+24%), GAAP EPS $0.72, non-GAAP EPS $0.91.","Royalty revenue $124.9M (+12% YoY) led by Phesgo, VYVGART Hytrulo, and Teriparatide launches.","Reiterated FY2024 guidance: rev $935-1015M, adj EBITDA $555-615M, non-GAAP EPS $3.65-4.05.","Partner approvals: Ocrevus SC (EU/UK), VYVGART Hytrulo for CIDP (US); BMS nivolumab SC PDUFA Dec 29, 2024.","Completed $250M ASR (6.5M shares at $38.35); new EU patent extends ENHANZE royalty through March 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":1.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":427232000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220416,"accession_number":"0001159036-24-000036","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Halozyme Q1 revenue up 21% to $196M; non-GAAP EPS $0.79, net income $76.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $195.9M (+21% YoY), driven by 21% royalty growth to $120.6M from DARZALEX and Phesgo.","GAAP diluted EPS $0.60; non-GAAP diluted EPS $0.79, vs $0.29 and $0.47 in Q1 2023.","Adjusted EBITDA $115.7M, up 56% from $74.3M; cash and securities $463.5M at quarter end.","Reiterated FY 2024 guidance: revenue $915-985M, adjusted EBITDA $535-585M, non-GAAP EPS $3.55-$3.90.","New $750M share repurchase program announced; partner milestones include $15M from BMS for nivolumab SC."],"consensus_eps_estimate":null,"consensus_eps_actual":0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":195879000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220415,"accession_number":"0001159036-24-000031","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Halozyme stockholders elect directors, approve executive compensation and charter amendment at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Barbara Duncan elected with 90.1M votes for, Mahesh Krishnan with 104.0M votes for, each to three-year term.","Advisory vote on named executive officer compensation passed 102.9M for vs 2.2M against.","Amendment to certificate of incorporation to exculpate officers approved 91.5M for vs 13.6M against; filed with Delaware on April 25.","Ratification of Ernst & Young as auditor for FY2024 passed 114.9M for vs 0.6M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240058,"accession_number":"0001159036-24-000007","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Halozyme Q4 revenue $230M (+27% YoY); reiterates 2024 guidance; $750M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $230M (+27% YoY); GAAP EPS $0.65, non-GAAP EPS $0.82; FY23 revenue $829M (+26%).","2024 guidance: revenue $915-985M (10-19% growth), non-GAAP EPS $3.55-3.90 (28-41% growth).","New $750M share repurchase program announced, reflecting confidence in growth.","Partner milestones: argenx VYVGART Hytrulo FDA priority review for CIDP (PDUFA June 21); $23M milestone.","Roche's Tecentriq SC received EU approval; Takeda's HYQVIA approved for CIDP in US and EU."],"consensus_eps_estimate":null,"consensus_eps_actual":2.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":829253000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240057,"accession_number":"0001159036-24-000003","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2024-01-17T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Halozyme prelim FY2023 revenue $827-832M; GAAP EPS $2.18-2.21","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue estimated $827-832M; royalties $445-450M for FY2023.","Net income $292-297M; EBITDA $435-440M; adjusted EBITDA $425-430M.","GAAP diluted EPS $2.18-2.21; non-GAAP diluted EPS $2.77-2.80.","Preliminary unaudited estimates subject to completion of year-end close."],"consensus_eps_estimate":null,"consensus_eps_actual":2.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":829253000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257569,"accession_number":"0001159036-23-000056","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Halozyme Q3 royalty revenue up 15% to $114.4M; raises 2023 EBITDA & EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.61, non-GAAP $0.75; royalty revenue $114.4M (+15% YoY).","Total revenue $216M (+3% YoY); operating income $88.3M vs $83.3M.","Accelerates remaining $250M share repurchase into 2023 via ASR (immediate).","Raises 2023 EBITDA guidance to $430-445M, non-GAAP EPS to $2.70-2.80.","Partner milestones: positive CheckMate-67T, Phesgo Japan approval, Tecentriq SC US launch delay to 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":1.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":599214000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274916,"accession_number":"0001159036-23-000051","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2023-09-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Roche delays US launch of Tecentriq SC with Halozyme's ENHANZE to 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Roche informed Halozyme on Sept 6, 2023 of US launch delay for Tecentriq SC due to required CMC updates.","CMC process updates expected to finish in 2023, enabling potential US launch in 2024.","Ex-US filings for Tecentriq SC remain unaffected by the delay.","Delay could impact Halozyme's royalty revenue from US sales until 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274915,"accession_number":"0001159036-23-000047","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Halozyme Q2: revenue $221M, GAAP EPS $0.56, Non-GAAP $0.74; raises FY EPS guidance to $2.65-$2.75","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $221.0M, +45% YoY; GAAP diluted EPS $0.56 vs $0.16 YoY; non-GAAP diluted EPS $0.74 vs $0.53.","Royalty revenue record $111.7M (+31% YoY), driven by subcutaneous DARZALEX.","Raised 2023 non-GAAP diluted EPS guidance to $2.65-$2.75 from $2.50-$2.65; revenue guidance $825-$845M.","FDA approval of VYVGART Hytrulo (argenx) for gMG triggered $33M milestones and royalties.","Positive Phase 3 data from Roche's SC ocrelizumab and argenx's CIDP trial support pipeline growth."],"consensus_eps_estimate":null,"consensus_eps_actual":0.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":383181000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292274,"accession_number":"0001159036-23-000037","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Halozyme Q1 revenue up 38% to $162M; GAAP EPS $0.29; reiterates 2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $162.1M (+38% YoY); royalty revenue $99.6M (+43% YoY).","GAAP diluted EPS $0.29; non-GAAP diluted EPS $0.47 (flat YoY).","Q1 net income $39.6M vs $60.1M in Q1 2022; EBITDA $74.3M.","Reiterates 2023 guidance: total revenue $815-845M, non-GAAP EPS $2.50-$2.65.","Repurchased 4.2M shares for $150M in Q1; $275.6M cash end of quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":162143000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292273,"accession_number":"0001159036-23-000033","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Halozyme stockholders elect three Class I directors and approve 2023 auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All three Class I director nominees elected: Connaughton, Miyashita, Posard, with majority votes.","Advisory vote on executive compensation approved with 107.6M for vs 4.7M against (95.8% support).","Stockholders chose annual frequency for future advisory votes on executive compensation (110.4M for one year).","Ratification of Ernst & Young as auditor for FY2023 approved with 123.3M votes for (98.8% of votes cast).","Turnout: 124.5M shares represented out of 135.4M outstanding (92% attendance)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312982,"accession_number":"0001159036-23-000020","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2023-03-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Halozyme says EPO revokes Janssen co-formulation patent; reaffirms 2023 guidance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EPO Opposition Division revoked Janssen's European Patent EP3370770B1 for DARZALEX SC co-formulation.","Halozyme reiterates 2023 revenue guidance of $815M-$845M and royalty revenue of $445M-$455M.","Affirms total royalty revenue projection of ~$1B by 2027 and thereafter to at least 2030.","License with Janssen: co-formulation patents do not extend royalty step-down beyond 2024 in EU, 2027 in US.","Written decision expected in months; if appeal filed, patent remains in force until final decision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312981,"accession_number":"0001159036-23-000017","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Halozyme discloses minimal SVB exposure; deposits insured, custodial accounts at separate banks","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash deposit at SVB under $250,000 FDIC limit as of March 10, 2023.","Majority of cash and investments held in custodial accounts at independent institutions; SVB is agent only.","SVB is a lender on $575M credit facility with $39M commitment; no current draws and no plans to draw.","Treasury/Fed/FDIC joint statement ensures all depositors are fully protected; money available March 13."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312980,"accession_number":"0001159036-23-000014","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director James M. Daly to resign from Halozyme board at end of 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James M. Daly notified Halozyme of his resignation from the Board, effective December 31, 2023.","Resignation is not due to any disagreement with the Company, its operations, strategy, management, or Board.","Mr. Daly's departure is planned nearly a year in advance, allowing for orderly succession."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312979,"accession_number":"0001159036-23-000011","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2023-02-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Halozyme Q4 revenue up 78% to $181M; 2023 guidance $815-845M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $181M (+78% YoY); full-year revenue $660.1M (+49% YoY).","Q4 GAAP diluted EPS $0.42; non-GAAP diluted EPS $0.48. Full-year GAAP EPS $1.44; non-GAAP EPS $2.21.","Record Q4 royalty revenue $106M (+69% YoY); full-year royalties $360.5M (+77% YoY).","2023 guidance: revenue $815-845M (23-28% growth), EBITDA $415-440M (>30% growth), non-GAAP EPS $2.50-2.65.","Completed $110M ASR; $350M of $750M buyback executed; elected Barbara Duncan to board."],"consensus_eps_estimate":null,"consensus_eps_actual":1.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":660116000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312978,"accession_number":"0001159036-23-000006","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2023-02-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Halozyme elects Barbara Duncan to Board of Directors; Audit Committee assignment","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Barbara Duncan elected to Board on Feb 3, 2023, with term expiring at 2024 annual meeting.","Initially assigned to serve on the Audit Committee.","Compensation follows non-employee director program; no related-party transactions disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312977,"accession_number":"0001159036-23-000004","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2023-01-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Halozyme guides FY2023 revenue $815M-$845M, >20% growth; Non-GAAP EPS $2.50-$2.65","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 total revenue guidance $815M-$845M, >20% growth over expected 2022 record revenue >$655M.","Royalty revenue guided $445M-$455M (>20% growth); EBITDA $415M-$440M (>30% growth).","Non-GAAP diluted EPS guidance $2.50-$2.65; up to $150M share repurchases under $750M authorization.","Anticipates two ENHANZE SC launches (efgartigimod, atezolizumab) and four Phase 3 data readouts in 2023.","Completed Antares Pharma acquisition in 2022; expects continued strength in DARZALEX SC and Phesgo royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":1.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":660116000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331498,"accession_number":"0001159036-22-000058","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Halozyme Q3 revenue $209M (+80% YoY); GAAP EPS $0.44, non-GAAP $0.74","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Royalty revenue $99.6M (+70% YoY) driven by DARZALEX SC and Phesgo.","Reiterates FY 2022 revenue guidance $655-685M; non-GAAP EPS $2.10-2.25.","Completed $720M convertible notes offering; repurchased $200M shares YTD.","Antares Pharma acquisition contributed product sales; operating income $83.3M.","Partner milestones: Roche Tecentriq SC met endpoints, argenx BLA for efgartigimod SC."],"consensus_eps_estimate":null,"consensus_eps_actual":1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":478620000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349030,"accession_number":"0001193125-22-225456","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2022-08-19T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Halozyme ups revolver to $575M, repays term loan and revolver with convertible note proceeds","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Revolving credit facility increased by $225M to $575M; all other terms unchanged.","Company repaid entire term loan facility and all outstanding revolver borrowings using proceeds from previously issued convertible notes.","Amendment included 11 increase lenders: Bank of America, Wells Fargo, JPMorgan, Citibank, Goldman Sachs, Mizuho, Silicon Valley Bank, and others.","Conditions included pro forma Consolidated Net Leverage Ratio not exceeding 0.25:1.00 less than the permitted level."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349029,"accession_number":"0001193125-22-224202","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2022-08-18T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Halozyme issues $720M 1.00% convertible notes due 2028; repays term loan, buys back shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $720M in 1.00% Convertible Senior Notes due 2028, including $95M from over-allotment option.","Net proceeds ~$701.4M; used to repay $250M term loan, exchange $77.6M of existing notes, and repurchase $90M of common stock.","Initial conversion price ~$56.02 per share; capped call transactions limit dilution with cap price $75.4075.","Increased 2022 stock repurchase authorization to $200M (from $100M) to commence after offering close.","Capped call transactions entered with multiple counterparties to reduce dilution upon conversion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349028,"accession_number":"0001193125-22-221861","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2022-08-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Halozyme upsizes and prices $625M convertible notes due 2028, conversion premium ~30%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$625M aggregate principal; initial purchasers have option for additional $95M.","1.00% annual interest rate; conversion price ~$56.02/share, 30% above $43.09 close.","Use of proceeds: ~$77.6M to exchange existing 2024 notes, up to $200M for share repurchases, $250M term loan repayment.","Entered capped call transactions with initial cap price ~$75.41/share to reduce dilution.","Expects to close offering on August 18, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349027,"accession_number":"0001193125-22-220557","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Halozyme proposes $500M convertible notes due 2028, plans $200M share repurchase and debt repayment","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$500M aggregate principal of convertible senior notes due 2028; initial purchasers have option for additional $75M.","Proceeds uses: up to $200M share repurchases (increase of $100M vs prior 2022 plan), exchange of existing 1.25% convertibles, and repayment of $250M term loan due 2026.","Capped call transactions will be entered to reduce potential dilution upon conversion of the notes.","Interest rate and conversion rate determined at pricing; conversions settled in cash plus stock if applicable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349026,"accession_number":"0001159036-22-000048","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Halozyme Q2 revenue up 12% to $152.4M, raises FY22 revenue guidance to $655-685M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.16; non-GAAP diluted EPS $0.53. Royalty revenue $85.3M (+86% YoY).","FY22 guidance raised: total revenue $655-685M (prior $530-560M); non-GAAP EPS $2.10-2.25.","Antares Pharma acquisition closed May 2022; expected to add $115-125M revenue in FY22.","Operating income $34.1M vs $93.0M in Q2 2021, reflecting Antares-related transaction costs.","Cash and marketable securities $209.4M on June 30, 2022, down from $740.9M at Dec 31, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":269644000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349025,"accession_number":"0001159036-22-000051","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","form_type":"8-K/A","filed_at":"2022-08-09T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Halozyme completes Antares acquisition for $5.60/sh; total consideration ~$1.0457B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Aggregate purchase consideration $1,045.7M; each Antares share converted into $5.60 cash.","Pro forma combined 2021 revenue $627.3M, net income $286.2M; basic EPS $2.04.","Pro forma Q1 2022 revenue $158.8M, net income $36.2M; basic EPS $0.26.","Financing includes $250M term loan and $350M revolving credit facility from BofA.","Nonrecurring acquisition-related costs of $40.5M expensed in pro forma statements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":8203275190.817186,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-08-09T23:59:59+00:00|349025"}